Can Den­dreon’s new Provenge da­ta help ig­nite a turn­around for the fad­ed can­cer star?

Two years ago, when Valeant bought Den­dreon and its prostate can­cer cell ther­a­py Provenge out of bank­rupt­cy for $400 mil­lion, ob­servers marked it as an­oth­er step down a long and bumpy spi­ral for a treat­ment that had once been cel­e­brat­ed as a his­toric break­through. Valeant was the sole bid­der and a bad match.

Then CEO J. Michael Pear­son called the ac­qui­si­tion an ef­fec­tive way to launch Valeant in­to the can­cer field — but Pear­son wasn’t head­ed any­where. A year lat­er, the CEO was out the door and Valeant was in ut­ter dis­ar­ray as its busi­ness mod­el of buy­ing drugs and jack­ing the price be­came a ra­dioac­tive source of con­tro­ver­sy.

Provenge, though, has sur­vived the lat­est chap­ter of its trou­bled his­to­ry. A Chi­nese com­pa­ny, San­pow­er Group, struck a deal to buy the cell ther­a­py — built from cells ex­tract­ed from pa­tients — for $820 mil­lion, look­ing to pen­e­trate the huge Chi­nese can­cer drug mar­ket.  And the ex­ec­u­tive crew that runs Den­dreon re­leased new “re­al world” da­ta over the week­end to un­der­score its ef­fec­tive­ness among African-Amer­i­can men, push­ing to ex­pand the mar­ket and aware­ness for a drug that had been eclipsed by Xtan­di and Zyti­ga.

When the FDA ap­proved Provenge 7 years ago, it re­quired Den­dreon to set up a pa­tient reg­istry to track its im­pact. And now Den­dreon, look­ing to stage a come­back, has post­ed some of the new da­ta they’ve drawn from the reg­istry to un­der­score its po­ten­tial for a sub­set of African-Amer­i­can pa­tients primed to de­liv­er the best out­comes.

Com­par­ing African-Amer­i­cans and whites with sim­i­lar base­line char­ac­ter­is­tics, Den­dreon notes that they tracked an over­all sur­vival ben­e­fit of 9.3 months com­pared with Cau­casians (37.3 months vs 28.0 months, re­spec­tive­ly). And if you re­strict to pa­tients with PSA lev­els be­low me­di­an amounts, “African-Amer­i­can pa­tients demon­strat­ed an ad­di­tion­al OS ben­e­fit of near­ly two ad­di­tion­al years (20.9 months) com­pared with Cau­casian pa­tients (54.3 months vs. 33.4 months, re­spec­tive­ly).”

The da­ta were pre­sent­ed over the week­end at the 112th Amer­i­can Uro­log­i­cal As­so­ci­a­tion An­nu­al Meet­ing in Boston by lead au­thor A. Oliv­er Sar­tor.

Jim Caggiano

Jim Caggiano, pres­i­dent of Den­dreon, says the da­ta un­der­score the val­ue of us­ing Provenge at an ear­ly stage of the dis­ease, par­tic­u­lar­ly among African-Amer­i­can men who suf­fer from a sig­nif­i­cant­ly high­er risk of death from prostate can­cer.

“Den­dreon is back and bet­ter than ever,” Caggiano told me ahead of the da­ta re­view. “These find­ings are im­por­tant for all men.”

These new da­ta mark a big step to­ward ex­pand­ing the mar­ket for Provenge, says Caggiano, who was orig­i­nal­ly hired in­to Den­dreon by for­mer CEO Mitch Gold back in 2004 as the head of its sales ef­fort.

Gold, now back at work as a biotech en­tre­pre­neur, al­so out­lined some huge sales fore­casts that caused quick and painful trou­ble for Den­dreon. With new, more eas­i­ly ad­min­is­tered drugs ri­val­ing Provenge, the au­tol­o­gous cell ther­a­py nev­er had a chance to com­pare well.

Caggiano, though, says that the drug is be­ing used by a grow­ing group of pa­tients. Last year about 4,000 men were treat­ed with Provenge, he says, up from about 3,500. And San­pow­er’s will­ing­ness to pay more than twice what Valeant need­ed to pluck it out of bank­rupt­cy un­der­scores the grow­ing at­trac­tion.

San­pow­er should com­plete the buy­out soon, says Caggiano, and that will set the stage for new stud­ies to test Provenge with surgery and ra­di­a­tion, look­ing for ev­i­dence that an ag­gres­sive com­bi­na­tion can be cu­ra­tive.

Provenge is a long way from dy­ing out, says the Den­dreon pres­i­dent with all the en­thu­si­asm of a head cheer­leader. And he in­tends to try. But not every­one at the meet­ing was im­pressed.


Lessons for biotech and phar­ma from a doc­tor who chased his own cure

After being struck by a rare disease as a healthy third year medical student, David Fajgenbaum began an arduous journey chasing his own cure. Amidst the hustle of this year’s JP Morgan conference, the digital trials platform Medable partnered with Endpoints Studio to share Dr. Fajgenbaum’s story with the drug development industry.

What follows is an edited transcript of the conversation between Medable CEO Dr. Michelle Longmire and Dr. Fajgenbaum, and it is full of lessons for biotech executives charged with bringing the next generation of medicines to patients.

Christos Kyratsous (via LinkedIn)

He built a MERS treat­ment in 6 months and then the best Ebo­la drug. Now Chris­tos Kyrat­sous turns his sights on Covid-19

TARRYTOWN, NY — In 2015, as the Ebola epidemic raged through swaths of West Africa, Kristen Pascal’s roommates sat her down on their couch and staged an intervention.

“Are you sure this is what you want to be doing with your life?” she recalls them asking her.

Pascal, a research associate for Regeneron, had been coming home at 2 am and leaving at 6 am. At one point, she didn’t see her roommate for a week. For months, that was life in Christos Kyratsous’ lab as the pair led a company-wide race to develop the first drug that could effectively treat Ebola before the outbreak ended. For Pascal, that was worth it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,400+ biopharma pros reading Endpoints daily — and it's free.

Left to right, top to bottom: Carl Gordon, Adam Stone, Peter Moglia, David Schenkein, Robert Nelsen, Carol Gallagher; Srinivas Akkaraju, Ray Debbane, Jim Flynn, Peter Kolchinsky, Thilo Schroeder, Brad Bolzon

UP­DAT­ED: The top 100 bio­phar­ma ven­ture in­vestors at the mega­bil­lions deal ta­ble

The VC crowd took a step back last year, but nevertheless maintained a furious pace of new investments in therapeutic tech platforms and biotech startups. And the top 100 players completely dominated the megabillions game.

Just looking at the number of deals done by each of the top 100, OrbiMed came in at the top, with 20, followed by Alexandria (18), Perceptive (16) and the ubiquitous RA Capital at 16. It’s impossible to say exactly how much they invested in total — those numbers are only rarely provided — but it is clear from the numbers assembled by Chris Dokomajilar at DealForma who’s most likely to be found sitting at the table during the go-go days of biotech investing.

Dokomajilar tracked $14.06 billion in biotech venture investing last year, a dip from the frenzied pace of $16.02 billion in 2018 and more than $10 billion higher than he recorded for 2010, as the economy was recovering from a profound economic crisis.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Rahul Ballal, Imara

As sick­le cell pa­tients find new op­tions, NEA-found­ed Imara pitch­es mid-stage al­ter­na­tive for $86M IPO

November 2019 proved to be a fruitful month for patients with blood disorders known as hemoglobinopathies. Within days, the FDA ushered two drugs for sickle cell disease and another for beta thalassemia to the market — livening up a barren field.

Imara, a relatively young plower, is riding on that enthusiasm as it shoots for an $86.25 million IPO.

Imara emerged from New Enterprise Associates’ orphan drug accelerator Cydan in 2016 as a single-product company. $77.3 million in private financing later IMR-687 remains the sole asset in its pipeline; the difference is the drug is now in Phase II for sickle cell disease, with topline data slated for later this year and two other mid-stage beta thalassemia studies lined up.

UP­DAT­ED: RA joins glob­al syn­di­cate to back a $98M round for CAN­bridge

A Beijing-based rare disease and oncology player has raised $98 million to help fund the expansion of its pipeline as well as a commercial portfolio.

CANbridge put out word Tuesday that the global private equity player General Atlantic joined forces with Chinese CRO Wuxi AppTec to lead the Series D, with both ready to chip in an extra $10 million each under the right conditions. The syndicate includes RA Capital Management, Hudson Bay Capital Management, YuanMing Prudence Fund and Tigermed.

Carol Robinson, Professor Dame Carol Robinson Research Group

UP­DAT­ED: Drug dis­cov­ery in HD: Ox­ford spin­of­f's mass spec­trom­e­try ap­proach scores fresh fund­ing

The technology used to detect explosives at airports — mass spectrometry — is being piloted as an engine for drug discovery.

Mass spectrometry is a tool designed to measure with profound accuracy the mass of a single molecule. Typically, mass spectrometers can be used to identify unknown compounds, to quantify known compounds, and to determine the structure and chemical properties of molecules.

Lars Fruergaard Jørgensen, chief executive officer of Novo Nordisk A/S, (via Getty Images)

The list of the 11 block­busters-to-be in line for a 2020 launch high­light agony and ec­sta­sy of drug R&D

For all the talk about unmet medical need and patients first and so on, the key criteria investors watch for any new drug in the pipelines is peak sales projection. Are you going to hit the blockbuster mark, at $1 billion-plus, or are you going to be an also-ran in the sales department?

Of course, analysts’ peak sales projections by themselves are of limited value in many cases. When the PCSK9 drugs started arriving 5 years ago, Repatha was billed as a $2.5 billion peak earner. They’re nowhere near that, with new competition threatening current levels. And if Biogen’s controversial Alzheimer’s drug aducanumab (submission planned but not on the list) is approved, per chance, will payers cover it?

Maybe not. And then those $10 billion in peak sales assumptions would go straight down the drain.

But, analysts are analysts, and peak sales projections have to be factored in when assessing the top experimental drugs up for a launch in the year ahead.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Chi­na ap­proves flu drug be­ing tout­ed as a po­ten­tial coro­n­avirus treat­ment amid a rush of clin­i­cal stud­ies

One of the three drugs that China’s Ministry of Science and Technology has tapped as potential COVID-19 treatments to watch has notched its first Chinese OK — for the flu.

While there’s no proof yet that fapilavir, or favipiravir, is the cure that patients and physicians are yearning for, it stands out for a unique constellation of qualities. It’s been commercially available in Japan for several years (unlike Gilead’s experimental remdesivir) yet it’s new to China (unlike the malaria drug chloroquine phosphate). Perhaps more importantly, a domestic biotech — Zhejiang Hisun Pharma — owns the rights to manufacture and market the drug, preempting any concerns about patents.

FDA goes on high alert as coro­n­avirus rais­es threat to drug man­u­fac­tur­ing and clin­i­cal tri­als grind to a halt

The FDA isn’t quite sure just what the coronavirus outbreak in China will mean for the US pharma industry, but it has the potential to trigger a host of troublesome issues around the supply chain the country is directly plugged into.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,400+ biopharma pros reading Endpoints daily — and it's free.